Trial Profile
Planned phase III trial of SyB D-0701 for the prevention of nausea and vomiting following emetogenic chemotherapy
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 01 Feb 2013
Price :
$35
*
At a glance
- Drugs Granisetron (Primary)
- Indications Chemotherapy-induced nausea and vomiting
- Focus Registrational; Therapeutic Use
- 11 Aug 2006 New trial record.